Navigation Links
Merck KGaA and Nano-Terra Announce Extension of Nanotechnology Solutions Alliance
Date:10/7/2008

building on these developments to create specific products which we believe will provide significant benefits to our customers."
"Through its embrace of innovative technologies and applications, Merck continues to underscore its commitment as a pioneer in research and development," said Dr. Carmichael Roberts, Vice Chairman of Nano-Terra. "We are delighted to extend our working relationship with them and to enhance their exploration of how to best optimize materials to improve products and processes for its customers."

  • 2006, Merck bestowed on Professor Whitesides the prestigious Emanuel Merck Lectureship prize.

About Nano-Terra, Inc.

Nano-Terra is a privately-held research and development company which has field-exclusive licenses to more than 50 patents on work done by co-founder Dr. George Whitesides at the renowned Whitesides Lab at Harvard University, where he is the Woodford L. and Ann A. Flowers University Professor. He is the recipient of the 2007 Priestley Medal.

  • company leverages its intellectual property through co-development and other agreements with Fortune 500 industrial and manufacturing companies and the U.S. government. Nano-Terra's scientific methods can be used to fabricate advanced materials and devices that enhance existing products or create entirely new products in a broad range of areas. These include smart materials and surfaces; flexible electronics such as displays and electronic packaging; fuel cells, batteries and solar power devices; sensors; industrial products and processes; and a wide range of consumer goods. For more information, visit www.nanoterra.com.

About EMD Chemicals Inc.


    Source: PRWeb
    Copyright©2008 Vocus, Inc.
    All rights reserved  

    0

    GOOD

    Page: 1 2 3

    Related medicine news :

    1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
    2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
    3. The African Medical and Research Foundation (AMREF) Honors Merck & Co., Inc. with Global Corporate Philanthropy Award
    4. Merck & Co., Inc. Response to Todays New York Medicaid Suit
    5. Mylan Vice Chairman and CEO Robert J. Coury to Ring NYSE Closing Bell(R) in Celebration of Merck Generics Acquisition
    6. AHF Challenges Merck Over Steep Price of Its New AIDS Drug, Isentress
    7. ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan
    8. Dynavax and Merck & Co., Inc. Announce Partnership to Develop HEPLISAV(TM), an Investigational Hepatitis B Vaccine Currently in Phase 3
    9. The Lanier Law Firm Announces $4.85 Billion National Vioxx Settlement With Merck & Co. Inc.
    10. GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc.
    11. ICx Technologies Works With Merck & Co., Inc. to Develop Cancer Diagnostic Technology
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    Related Image:
     Merck KGaA and Nano-Terra Announce Extension of Nanotechnology Solutions Alliance 
    Merck KGaA and Nano-Terra Announce Extension of Nanotechnology Solutions Alliance
    (Date:12/17/2009)... On the heels of unveiling the new ... 2010 race, LA Marathon officials today announced a larger-than-ever ... funds for causes ranging from cancer research to gang ... charity program is in line with the vision of ... the potential to be a huge philanthropic force in ...
    (Date:12/17/2009)... -- China,s leading high-tech,healthcare group, Golden Meditech Company ... is pleased to announce today the interim results ... the Group,s two,associate companies made their debut on ... businesses have been strengthened, with maiden revenue and ... Mr. KAM Yuen, Chairman ...
    (Date:12/17/2009)... Maureen Neitz, the husband-and-wife team whose pioneering research may ... vision disorders, as the inaugural recipients of the Jay ... is funded by a $1 million endowment established this ... ,75 and Susan K. Feigenbaum ,74, his wife. The ... , The Neitzes, both of whom are faculty members ...
    (Date:12/17/2009)... monitor cell phone use in era of sexually explicit ... News) -- Teens and preteens spend hours sending text ... some of those messages -- sexually explicit material, giving ... concern among parents, University of Michigan researchers report. , ... percent of parents are worried about the time their ...
    (Date:12/17/2009)... hired Deirdre Byrne to lead the firm’s Interim Leadership division as ... experience in healthcare consulting, Byrne will assume her duties at B. ... ... 17, 2009 -- B. E. Smith recently hired Deirdre ... president. A seasoned executive with nearly 20 years of experience in ...
    Breaking Medicine News(10 mins):Health News:LA Marathon Unveils Expanded Charity Program; Sixty Official Charities to Take Part in 2010 Race 2Health News:LA Marathon Unveils Expanded Charity Program; Sixty Official Charities to Take Part in 2010 Race 3Health News:LA Marathon Unveils Expanded Charity Program; Sixty Official Charities to Take Part in 2010 Race 4Health News:Golden Meditech Announces Interim Results of FY2009/10 2Health News:Golden Meditech Announces Interim Results of FY2009/10 3Health News:Vision researchers Jay and Maureen Neitz to receive first Pepose Award from Brandeis 2Health News:'Sexting' by Kids Begets Fretting by Parents 2Health News:Deirdre Byrne Joins B. E. Smith as Senior Vice President, Interim Leadership Services 2Health News:Deirdre Byrne Joins B. E. Smith as Senior Vice President, Interim Leadership Services 3
    ... they are moving closer to understanding why the most ... to drug treatment in the past three decades. They ... in yeast, a protozoan gene that contributes to such ... a two-year period is believed to be the largest ...
    ... the U.S. Army to rescue injured or abducted soldiers, ... ,The 1.8-metre-tall Battlefield Extraction-Assist Robot (Bear) will be able ... while carrying an injured soldier in its arms, says ... ,The prototype Bear torso is being designed ...
    ... responded to a study and accompanying editorial on folic ... 6 issue of the Journal of the American Medical ... the media, and the government not to jump to ... recent years in encouraging supplementation and food fortification with ...
    ... become more tolerant about premarital sex, claims a survey. ... 2000-06", which was released this week, found that roughly ... ,Conducted by the Institute of Sexuality ... financed by the Ford Foundation, the survey polled over ...
    ... groups, joined by a labor union, have appealed ... health and safety protection from the endocrine-disrupting chemicals, ... sought a ban on the use of these ... safer alternatives are available. ,The current ...
    ... billion dollars) over the next eight years to the global ... to be published Thursday. ,Heidemarie Wieczorek-Zeul told ... to send a message to other member states during the ... Heiligendamm. ,"My appeal goes out to the other ...
    Other Medicine News:Health News:New Insights into Antimalarial Drug Resistance 2Health News:New Insights into Antimalarial Drug Resistance 3Health News:New Insights into Antimalarial Drug Resistance 4Health News:U.S. Army Developing a Robot to Rescue Injured Soldiers 2Health News:CRN Emphasizes Importance of Folic Acid Benefits 2Health News:Survey Finds Chinese are More Tolerant About Premarital Sex Now 2Health News:Environment Groups Appeal for Ban on Cleaning Chemicals 2
    (Date:12/16/2009)... According to Millennium Research Group (MRG), the global ... US minimally invasive spinal fusion market will expand ... 12% through 2014, reimbursement concerns in certain segments ... previously had been forecast at almost 20%. ,, ... Technologies 2010 report finds that ...
    (Date:12/16/2009)... Calif., Dec. 16 Accuray Incorporated (Nasdaq: ... radiosurgery, announced today that its president and chief executive ... at the 28th Annual J.P. Morgan Healthcare Conference in ... a.m. PT/12:30 p.m. ET. ,, A live webcast ... investor relations page of the Company,s Web site at ...
    (Date:12/16/2009)... (OTC Bulletin Board: HEWA) an online U.S. mail-order pharmacy, ... per annum short term debt financing. The structure ... $500,000, with accrued interest and principal repayable in one ... and principal repayable in one year from its funding, ... any calendar month prior to December 15, 2010. ...
    Breaking Medicine Technology:Reimbursement Difficulties With TranS1's AxiaLIF and NuVasive's XLIF Have Sceptics Talking 2Reimbursement Difficulties With TranS1's AxiaLIF and NuVasive's XLIF Have Sceptics Talking 3Accuray Incorporated to Present at 28th Annual J. P. Morgan Healthcare Conference 2HealthWarehouse.com, Inc. Secures $1 Million in Debt Financing 2NASCAR Camping World Truck Series Driver Aric Almirola Waves the Yellow Flag at Warning Signs of Skin Cancer 5659 1NASCAR Camping World Truck Series Driver Aric Almirola Waves the Yellow Flag at Warning Signs of Skin Cancer 5659 2NASCAR Camping World Truck Series Driver Aric Almirola Waves the Yellow Flag at Warning Signs of Skin Cancer 5659 3Emergency Use Authorization Granted For BioCrysts Peramivir 5654 1Emergency Use Authorization Granted For BioCrysts Peramivir 5654 2Emergency Use Authorization Granted For BioCrysts Peramivir 5654 3Emergency Use Authorization Granted For BioCrysts Peramivir 5654 4Scientists develop novel method to generate functional hepatocytes for drug testing 14576 1Scientists develop novel method to generate functional hepatocytes for drug testing 14576 2
    ... Dec. 11 Pharmasset, Inc.,(Nasdaq: VRUS ), a ... drugs to treat viral,infections, reported financial results for the fiscal ... $63.6 million in cash and cash,equivalents and short term investments. ... 2008 Highlights , Clevudine ...
    ... positive results from its pandemic influenza vaccine Phase IIa trial ... seasonal vaccine in the elderly in 2009 , ... Novavax, Inc. (Nasdaq: NVAX ) announced today favorable ... seasonal influenza VLP (trivalent) vaccine candidate. The vaccine, which ...
    Other Medicine Technology:Pharmasset Reports Fiscal Year End 2008 Financial Results 2Pharmasset Reports Fiscal Year End 2008 Financial Results 3Pharmasset Reports Fiscal Year End 2008 Financial Results 4Pharmasset Reports Fiscal Year End 2008 Financial Results 5Pharmasset Reports Fiscal Year End 2008 Financial Results 6Pharmasset Reports Fiscal Year End 2008 Financial Results 7Pharmasset Reports Fiscal Year End 2008 Financial Results 8Pharmasset Reports Fiscal Year End 2008 Financial Results 9Novavax Announces Top Line Results of Phase IIa Clinical Trial for Its Seasonal Influenza VLP (Trivalent) Vaccine Candidate 2Novavax Announces Top Line Results of Phase IIa Clinical Trial for Its Seasonal Influenza VLP (Trivalent) Vaccine Candidate 3Novavax Announces Top Line Results of Phase IIa Clinical Trial for Its Seasonal Influenza VLP (Trivalent) Vaccine Candidate 4Novavax Announces Top Line Results of Phase IIa Clinical Trial for Its Seasonal Influenza VLP (Trivalent) Vaccine Candidate 5Novavax Announces Top Line Results of Phase IIa Clinical Trial for Its Seasonal Influenza VLP (Trivalent) Vaccine Candidate 6
    Launcher Coronary Guide Catheter gives a dependable platform for optimal outcomes with absolute visualization and a proprietary design....
    ... Fast-Cath, Maximum, Maximum Xtra, and Maximum ... of standard and specialty hemostasis introducers ... as the premier hemostasis introducers for ... procedures including angiography, angioplasty, stenting, atherectomy, ...
    St. Jude Medical's line of guiding introducers includes Swartz Series, SAFL, SEPT, CSTA, RAMP, and 2 piece steerable...
    ... Ultimum hemostasis introducers provide ... wire-to-dilator and dilator-to-sheath transitions, high ... thickness. A dual layer sheath ... flexibility, and works with an ...
    Medicine Products: